Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | MPO | P05164 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.68 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | ITGB2 | P05107 | 5/20 | 0.62 |
| ▸ | ICAM1 | P05362 | 5/20 | 0.62 |
| ▸ | ITGAL | P20701 | 5/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
| ▸ | ECE1 | P42892 | 1/20 | 0.61 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL728052 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL27678972 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL8529176 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL16855056 | 0.89 | KDM4E (0.60) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL16855202 | 0.89 | KDM4E (0.60) | ACEKDM4EMEN1LMNAMPO | |
| Golotimod SCHEMBL12818886 | 0.88 | KDM4E (0.65) | ACEKDM4EMEN1LMNAMPO | |
| Golotimod SCHEMBL726938 | 0.88 | KDM4E (0.65) | ACEKDM4EMEN1LMNAMPO | |
| Orilotimod SCHEMBL29379690 | 0.88 | KDM4E (0.65) | ACEKDM4EMEN1LMNAMPO | |
| Golotimod SCHEMBL726291 | 0.88 | KDM4E (0.65) | ACEKDM4EMEN1LMNAMPO | |
| Golotimod SCHEMBL29622906 | 0.88 | KDM4E (0.65) | ACEKDM4EMEN1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1042286-B1 | GAMMA-GLUTAMYL AND BETA-ASPARTYL CONTAINING IMMUNOMODULATOR COMPOUNDS AND METHODS THEREWITH | CRAGMONT PHARMACEUTICALS LLC (US) | 2010-08-25 | — | — | EP | claimed |
| EP-1814566-B1 | TREATMENT OR PREVENTION OF HEMORRHAGIC VIRAL INFECTIONS WITH IMMUNOMODULATOR COMPOUNDS | SCICLONE PHARMACEUTICALS INC (US) | 2010-07-28 | — | — | EP | claimed |
| EP-2078525-A2 | Treatment of tuberculosis using immunomodulator compounds | SciClone Pharmaceuticals, Inc. (US) | 2009-07-15 | — | — | EP | claimed |
| US-7173013-B2 | Treatment of tuberculosis using immunomodulator compounds | SCICLONE PHARMACEUTICALS, INC. (US) | 2007-02-06 | — | — | US | claimed |
| US-20040259806-A1 | Treatment of tuberculosis using immunomodulator compounds | SCICLONE PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| CN-1155571-C | Gamma-glutamyl and beta-aspartyl containing immunomodulator compounds and methods of making the same | ������������ҩ�������ι�˾ | 2004-06-30 | — | — | CN | claimed |
| CN-1284943-A | Gamma-glutamyl and beta-aspartyl containing immunomodulator compounds and methods of making the same | WEI EDWARD T (US) | 2001-02-21 | — | — | CN | claimed |
| EP-1042286-A1 | GAMMA-GLUTAMYL AND BETA-ASPARTYL CONTAINING IMMUNOMODULATOR COMPOUNDS AND METHODS THEREWITH | Wei, Edward T. (US) | 2000-10-11 | — | — | EP | claimed |
| WO-1999033799-A1 | GAMMA-GLUTAMYL AND BETA-ASPARTYL CONTAINING IMMUNOMODULATOR COMPOUNDS AND METHODS THEREWITH | WEI EDWARD T (US) | 1999-07-08 | — | — | WO | claimed |
| US-5916878-A | DIPEPTIDE OF EITHER GAMMA-GLUTAMYL-L-TRYPTOPHAN OR BETA-ASPARTYL-L-TRYPTOPHAN; ADMINISTERING TO THE PATIENTS TO REDUCE THE RISKS INFECTIONS FROM MICROORGANISM | Wei, Edward T. (US) | 1999-06-29 | — | — | US | claimed |
| US-8193152-B2 | Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-06-05 | — | — | US | disclosed |
| WO-2012068412-A2 | METHOD AND COMPOSITIONS FOR TREATMENT OF STAT3-RESPONSIVE CANCERS AND/OR RENAL CANCER | SCICLONE PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
| US-8163702-B2 | Treatment of melanoma | SCICLONE PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110200558-A1 | Treatment or Prevention of Hepatitis C with Immunomodulator Compounds | SCICLONE PHARMACEUTICALS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110189305-A1 | TREATMENT OF LUNG CANCER | SCICLONE PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| WO-2003013572-A1 | TREATMENT OF TUBERCULOSIS USING IMMUNOMODULATOR COMPOUNDS | SCICLONE PHARMACEUTICALS, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
| CN-1284943-A | Gamma-glutamyl and beta-aspartyl containing immunomodulator compounds and methods of making the same | WEI EDWARD T (US) | 2001-02-21 | — | — | CN | disclosed |
| EP-1042286-A1 | GAMMA-GLUTAMYL AND BETA-ASPARTYL CONTAINING IMMUNOMODULATOR COMPOUNDS AND METHODS THEREWITH | Wei, Edward T. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033799-A1 | GAMMA-GLUTAMYL AND BETA-ASPARTYL CONTAINING IMMUNOMODULATOR COMPOUNDS AND METHODS THEREWITH | WEI EDWARD T (US) | 1999-07-08 | — | — | WO | disclosed |
| US-5916878-A | DIPEPTIDE OF EITHER GAMMA-GLUTAMYL-L-TRYPTOPHAN OR BETA-ASPARTYL-L-TRYPTOPHAN; ADMINISTERING TO THE PATIENTS TO REDUCE THE RISKS INFECTIONS FROM MICROORGANISM | Wei, Edward T. (US) | 1999-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259806-A1 | Treatment of tuberculosis using immunomodulator compounds | IFNG, IFNAR1, CD4 | ACE 2553/4885KDM4E 4329/4885MEN1 2589/4885 |
| US-20110189305-A1 | TREATMENT OF LUNG CANCER | TSG101, IFNG, LGALS2 | ACE 2437/4885KDM4E 2885/4885MEN1 3686/4885 |
| US-20110200558-A1 | Treatment or Prevention of Hepatitis C with Immunomodulator Compounds | HAVCR2, IFNG, HDGF | ACE 2024/4885KDM4E 3995/4885MEN1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.